Incidence and clinical features of cataracts: an under-recognized adverse event with mirvetuximab soravtansine-gynx in ovarian cancer
- DOI
- 10.1016/j.ijgc.2026.104733
- Published
- 2026-07
- Container
- International Journal of Gynecological Cancer
- Publisher
- Elsevier BV
- Open access
- unknown
Credibility signals
uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- supportingDOI registered: A matching record was returned by Crossref.
- supportingDOI resolves: A matching record was returned by Crossref.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- supportingMetadata completeness: All 6 scored descriptive metadata groups are present.
Cite this work
BibTeX
@article{allodium:10.1016/j.ijgc.2026.104733,
title = {Incidence and clinical features of cataracts: an under-recognized adverse event with mirvetuximab soravtansine-gynx in ovarian cancer},
author = {Matthew L. Flint and Anna Shvygin and Paul Johannet and Seth Cohen and Jason Konner and William P. Tew and Rachel N. Grisham and Jasmine H. Francis and Julia Canestraro and Roisin E. O’Cearbhaill},
year = {2026},
journal = {International Journal of Gynecological Cancer},
doi = {10.1016/j.ijgc.2026.104733},
url = {https://doi.org/10.1016/j.ijgc.2026.104733}
}RIS
TY - JOUR TI - Incidence and clinical features of cataracts: an under-recognized adverse event with mirvetuximab soravtansine-gynx in ovarian cancer AU - Matthew L. Flint AU - Anna Shvygin AU - Paul Johannet AU - Seth Cohen AU - Jason Konner AU - William P. Tew AU - Rachel N. Grisham AU - Jasmine H. Francis AU - Julia Canestraro AU - Roisin E. O’Cearbhaill PY - 2026 JO - International Journal of Gynecological Cancer DO - 10.1016/j.ijgc.2026.104733 UR - https://doi.org/10.1016/j.ijgc.2026.104733 ER -
APA
Flint, M. L., Shvygin, A., Johannet, P., Cohen, S., Konner, J., Tew, W. P., Grisham, R. N., Francis, J. H., Canestraro, J., & O’Cearbhaill, R. E. (2026). Incidence and clinical features of cataracts: an under-recognized adverse event with mirvetuximab soravtansine-gynx in ovarian cancer. International Journal of Gynecological Cancer. https://doi.org/10.1016/j.ijgc.2026.104733
Source records
- crossref · retrieved 2026-09-26T07:37:58.003Z